Even a little exercise linked with lower stroke risk in people with afib
Testosterone therapy without evidence of deficiency may boost heart risk
Weight-loss drug may lower risk of heart attacks and infections
What to eat on the DASH diet
Migraine: How it's diagnosed and what that means
Tricep workouts you can do at home
Mindfulness practices to reduce stress and improve focus
Antihistamines may not offer meaningful relief from eczema symptoms
Overweight and taking blood pressure medications: Study finds it's a trend that's working
FDA approves first mRNA-based flu vaccine
Daniel DeNoon
Executive Editor, Harvard Heart Letter
Daniel J. DeNoon is the former executive editor of the Harvard Heart Letter. He was senior medical writer for WebMD for 14 years. He was founding editor of the newsletter AIDSWeekly and covered the HIV/AIDS pandemic for this and other publications. DeNoon’s work has won a number of journalism awards, including several of the Society of Professional Journalists’ Sigma Delta Chi awards. He has served as a board member of ServeHaiti, a nonprofit group bringing healthcare to a remote region of Haiti. DeNoon is a graduate of Emory University, where he received a BA in psychology and religion.
Posts by Daniel DeNoon
Exercise and Fitness
Combine brief bouts of moderate exercise for health
Daniel DeNoon
Back pain often overdiagnosed and overtreated
Heart Health
A dog could be your heart’s best friend
Exercise and Fitness
Benefit to improving diet and exercise at the same time
Even a little exercise linked with lower stroke risk in people with afib
Testosterone therapy without evidence of deficiency may boost heart risk
Weight-loss drug may lower risk of heart attacks and infections
What to eat on the DASH diet
Migraine: How it's diagnosed and what that means
Tricep workouts you can do at home
Mindfulness practices to reduce stress and improve focus
Antihistamines may not offer meaningful relief from eczema symptoms
Overweight and taking blood pressure medications: Study finds it's a trend that's working
FDA approves first mRNA-based flu vaccine
